<DOC>
	<DOCNO>NCT00559715</DOCNO>
	<brief_summary>The study design demonstrate therapeutic non-inferiority recombinant humanize monoclonal VEGF antibody bevacizumab administer intravitreal injection treatment AMD comparison relate fragment ranibizumab .</brief_summary>
	<brief_title>Prevention Vision Loss Patients With Age-Related Macular Degeneration ( AMD ) Intravitreal Injection Bevacizumab Ranibizumab</brief_title>
	<detailed_description />
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients visual impairment ( best correct visual acuity 20/40 20/320 ( Snellen equivalent , ETDRS chart ) ) due active primary recurrent CNV associate agerelated macular degeneration involve foveal center , present either : classical / predominantly classical lesion large diameter SNVM small great distance major temporal vascular arcade minimally classical lesion occult lesion classic choroidal neovascularization Known suspect hypersensitivity ranibizumab bevacizumab Participation clinical trial within last 4 week Previous participation clinical trial ( either eye ) involve antiangiogenic drug ( pegaptanib , bevacizumab ranibizumab , anecortave acetate , protein kinase C inhibitor , etc . ) Previous intravitreal drug delivery ( e.g. , intravitreal corticosteroid injection device implantation ) study eye Previous subfoveal focal laser photocoagulation study eye Previous laser photocoagulation ( juxtafoveal extrafoveal ) study eye History vitreoretinal surgery study eye History submacular surgery surgical intervention AMD study eye Subretinal hemorrhage study eye involve fovea , size hemorrhage either 50 % total lesion area 1 disc area size Subfoveal fibrosis atrophy study eye CNV either eye due cause , ocular histoplasmosis , trauma , pathologic myopia Retinal pigment epithelial tear involve macula study eye Any concurrent intraocular condition study eye ( e.g. , cataract diabetic retinopathy ) , opinion investigator , could either : require medical surgical intervention 24month study period prevent treat visual loss might result condition , allow progress untreated , could likely contribute loss least 2 Snellen equivalent line BCVA 24month study period Active intraocular , ocular , periocular inflammation ( grade `` trace '' ) study eye Current vitreous hemorrhage study eye History rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye History idiopathic autoimmuneassociated uveitis either eye Infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye Aphakia absence posterior capsule study eye Spherical equivalent refractive error study eye demonstrate âˆ’8 diopter myopia Intraocular surgery ( include cataract surgery ) study eye within 2 month precede day 0 Uncontrolled glaucoma study eye ( defined intraocular pressure [ IOP ] 30 mmHg despite treatment antiglaucoma medication ) History glaucoma filter surgery study eye History corneal transplant study eye Premenopausal woman use adequate contraception History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render subject high risk treatment complication Current treatment active systemic infection History allergy fluorescein , amenable treatment diphenhydramine Inability obtain fundus photograph FA sufficient quality analyze grade blinded evaluation center Inability comply study followup procedure</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>macular degeneration</keyword>
	<keyword>age-related</keyword>
	<keyword>neovascular</keyword>
	<keyword>intravitreal injection</keyword>
	<keyword>vision loss</keyword>
	<keyword>outpatient set</keyword>
</DOC>